Table 1 Baseline characteristics of study patients, total and by diagnosis subgroups
Baseline diagnosis | P value | Total (838, 100%) | |||
|---|---|---|---|---|---|
CSA (n = 200) n (%) | UA (n = 154) n (%) | RA (n = 484) n (%) | |||
Female | 148(74.0) | 87(56.5) | 329(68.0) | 0.002 | 564(67.3) |
Age | |||||
18–39 | 74(37.0) | 36(23.5) | 87(18.0) | < 0.001 | 197(23.6) |
40–49 | 64(32.0) | 42(27.5) | 76(15.8) | 182(21.8) | |
50–59 | 39(19.5) | 36(23.5) | 143(29.7) | 218(26.1) | |
≥ 60 | 23(11.5) | 39(25.5) | 176(36.5) | 238(28.5) | |
Ethnicity | |||||
White | 128(66.0) | 97(65.1) | 317(66.6) | 0.4 | 543(66.2) |
Asian | 44(22.7) | 26(17.4) | 92(19.3) | 162(19.8) | |
Other | 22(11.3) | 26(17.4) | 67(14.1) | 115(14.0) | |
BMI | |||||
< 25 kg/m2 | 54(28.3) | 39(26.4) | 138(30.0) | 0.7 | 231(28.9) |
25–30 kg/m2 | 71(37.2) | 57(38.5) | 154(33.5) | 282(35.3) | |
≥ 30 kg/m2 | 66(34.6) | 52(35.1) | 168(36.5) | 286(35.8) | |
Smoking status | |||||
Never | 104(52.3) | 75(49.0) | 221(45.9) | 0.5 | 400(48.0) |
Current | 38(19.1) | 33(21.6) | 102(21.2) | 173(20.7) | |
Previous | 57(28.6) | 45(29.4) | 159(33.0) | 261(31.3) | |
IMD quintile | |||||
1st (most deprived) | 85(42.7) | 64(41.6) | 230(47.6) | 0.5 | 379(45.3) |
2nd | 42(21.1) | 33(21.4) | 107(22.2) | 182(21.8) | |
3rd | 37(18.6) | 36(23.4) | 76(15.7) | 149(17.8) | |
4th | 20(10.1) | 14(9.1) | 34(7.0) | 68(8.1) | |
5th (least deprived) | 15(7.5) | 7(4.5) | 36(7.5) | 58(6.9) | |
DAS-28 | |||||
Remission (< 2.6) | 72(36.6) | 41(27.0) | 14(2.9) | < 0.001 | 127(15.4) |
Low (≥ 2.6 to 3.2) | 42(21.3) | 31(20.4) | 24(5.0) | 97(11.7) | |
Moderate (≥ 3.2 to ≤ 5.1) | 80(40.6) | 71(46.7) | 214(44.9) | 365(44.2) | |
High (> 5.1) | 3(1.5) | 9(5.9) | 225(47.2) | 237(28.7) | |
Positive antibodies | 87(43.5) | 18(11.7) | 318(65.7) | < 0.001 | 423(50.5) |
Duration of symptoms | |||||
< 13 weeks | 28(14.0) | 40(26.5) | 124(25.8) | 0.002 | 192(23.1) |
13–26 weeks | 55(27.5) | 40(26.5) | 118(24.5) | 213(25.6) | |
27–52 weeks | 52(26.0) | 28(18.5) | 127(26.4) | 207(24.9) | |
≥ 53 weeks | 65(32.5) | 43(28.5) | 112(23.3) | 220(26.4) | |
Polypharmacy | |||||
≥ 5 medications | 31(15.5) | 28(18.2) | 133(27.5) | 0.001 | 192(22.9) |